Floatz Rating
B60/100
Confidence
Indicative
Sponsor
AbbVie
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07024784CT.gov A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | — | Recruiting | — | — | — |
NCT05564377CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | — | Recruiting | — | — | — |
NCT04065269CT.gov ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss | — | Active Not Recruiting | — | — | — |
NCT03162627CT.gov Selumetinib and Olaparib in Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Female Reproductive Organ Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | AbbVie | P2 | B · 60 |
| Adriamycin | AstraZeneca | P2 | BB |
| Carboplatin | AbbVie | P2/3 | BB |
| Indocyanine Green | Istanbul University | P4 | BB |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | B |
| Atezolizumab | M.D. Anderson Cancer Center | P2 | B |
| Nivolumab | Clovis Oncology, Inc. | P2 | B |
| Ringer'S Acetate | Joachim Zdolsek | P4 | B |
| Normal Human Serum Albumin | Joachim Zdolsek | P4 | B |
+42 more in the Female Reproductive Organ Cancer cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Female Reproductive Organ Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-female-reproductive-organ-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →